Home/Pipeline/SA-033

SA-033

Liver Cancer

Pre-clinicalActive

Key Facts

Indication

Liver Cancer

Phase

Pre-clinical

Status

Active

Company

Double Bond Pharmaceutical

About Double Bond Pharmaceutical

Double Bond Pharmaceutical is a private, preclinical-stage biotech company leveraging its proprietary BeloGal® drug delivery platform to enhance the efficacy and safety of existing medicines. The company's strategy centers on reformulating proven drugs for targeted local or organ-specific delivery, with lead programs in oncology and infectious diseases. Based in Uppsala, Sweden, DBP aims to address significant unmet needs in glioblastoma, liver cancer, and pneumonia by improving therapeutic profiles and reducing systemic toxicity.

View full company profile

Therapeutic Areas

Oncology Infectious Disease

Other Liver Cancer Drugs

Drug	Company	Phase	Status
CY-101	Cytovation	Phase 1	Completed
PRDM2 Target	ARIZ Precision Medicine	Discovery	Active
PanGIA Liver	PanGIA Biotech	Pre-clinical	Active
Ad-SGE-REIC + Anti-tumor Agent	Momotaro-Gene	Preclinical/Research	Patent Filed
Alpha DaRT	Alpha Tau Medical	Not Specified	Active, Recruiting